Published in Arthritis Rheum on March 01, 2003
Identification and functional characterization of T cells reactive to citrullinated vimentin in HLA-DRB1*0401-positive humanized mice and rheumatoid arthritis patients. Arthritis Rheum (2011) 2.13
Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest (2009) 2.12
The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med (2006) 2.11
Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther (2006) 1.45
Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther (2011) 1.35
Immunological control of tuberculosis: role of tumour necrosis factor and more. Ann Rheum Dis (2005) 1.31
Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches. Arthritis Res (2002) 1.21
Decreased expression of microRNA-21 correlates with the imbalance of Th17 and Treg cells in patients with rheumatoid arthritis. J Cell Mol Med (2014) 1.03
Cytokines in the seronegative spondyloarthropathies and their modification by TNF blockade: a brief report and literature review. Ann Rheum Dis (2003) 0.97
Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis. Patient Prefer Adherence (2013) 0.92
Infliximab and etanercept are equally effective in reducing enterocyte APOPTOSIS in experimental colitis. Int J Med Sci (2008) 0.92
Preferential type 1 chemokine receptors and cytokine production of CD28- T cells in ankylosing spondylitis. Ann Rheum Dis (2005) 0.85
Intracellular and surface RANKL are differentially regulated in patients with ankylosing spondylitis. Rheumatol Int (2008) 0.83
Cytomegalovirus colitis in a patient with Behcet's disease receiving tumor necrosis factor alpha inhibitory treatment. World J Gastroenterol (2008) 0.82
Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis. Ann Rheum Dis (2005) 0.82
Atypical infectious mononucleosis in a patient receiving tumor necrosis factor alpha inhibitory treatment. Rheumatol Int (2008) 0.77
The impact of disease activity and tumour necrosis factor-α inhibitor therapy on cytokine levels in juvenile idiopathic arthritis. Clin Exp Immunol (2016) 0.75
Analysis of Th Cell-related Cytokine Production in Behçet Disease Patients with Uveitis Before and After Infliximab Treatment. Ocul Immunol Inflamm (2016) 0.75
Effect of infliximab treatment on T cell cytokine responses in spondylarthropathy: comment on the article by Zou et al. Arthritis Rheum (2004) 0.75
Management of ankylosing spondylitis with infliximab. Open Access Rheumatol (2009) 0.75
Anti-tumor Necrosis Factor Alpha (Infliximab) Attenuates Apoptosis, Oxidative Stress, and Calcium Ion Entry Through Modulation of Cation Channels in Neutrophils of Patients with Ankylosing Spondylitis. J Membr Biol (2016) 0.75
Ankylosing spondylitis. Lancet (2007) 6.58
Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis. Arthritis Rheumatol (2015) 4.41
Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum (2005) 4.12
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet (2013) 3.83
DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells. Eur J Immunol (2007) 3.80
Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2006) 3.51
Two subsets of naive T helper cells with distinct T cell receptor excision circle content in human adult peripheral blood. J Exp Med (2002) 3.43
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis (2013) 3.43
CD56brightCD16- killer Ig-like receptor- NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. J Immunol (2007) 2.97
Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int (2002) 2.95
Direct access to CD4+ T cells specific for defined antigens according to CD154 expression. Nat Med (2005) 2.92
Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum (2008) 2.75
The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum (2005) 2.74
Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum (2006) 2.67
Non-invasive measurement of brain viscoelasticity using magnetic resonance elastography. NMR Biomed (2008) 2.66
2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis (2011) 2.61
The microRNA miR-182 is induced by IL-2 and promotes clonal expansion of activated helper T lymphocytes. Nat Immunol (2010) 2.53
Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol (2014) 2.52
Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum (2008) 2.48
The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum (2009) 2.45
Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis (2010) 2.34
The impact of aging and gender on brain viscoelasticity. Neuroimage (2009) 2.15
The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration's comments and concerns. Arthritis Rheumatol (2014) 2.14
Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes. Arthritis Rheum (2008) 2.14
Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis (2012) 2.10
Noninvasive assessment of the rheological behavior of human organs using multifrequency MR elastography: a study of brain and liver viscoelasticity. Phys Med Biol (2007) 2.08
Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum (2008) 2.04
MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multilevel analysis in patients with ankylosing spondylitis. Ann Rheum Dis (2011) 1.90
Correlation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis. Arthritis Res Ther (2006) 1.88
Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. J Rheumatol (2005) 1.84
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med (2015) 1.83
MR-elastography reveals degradation of tissue integrity in multiple sclerosis. Neuroimage (2009) 1.83
Life after the thymus: CD31+ and CD31- human naive CD4+ T-cell subsets. Blood (2008) 1.82
Assessment of liver viscoelasticity using multifrequency MR elastography. Magn Reson Med (2008) 1.80
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis (2013) 1.74
Are spondylarthritides related but distinct conditions or a single disease with a heterogeneous phenotype? Arthritis Rheum (2013) 1.69
Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial. Ann Rheum Dis (2012) 1.68
In vivo viscoelastic properties of the brain in normal pressure hydrocephalus. NMR Biomed (2010) 1.67
Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum (2012) 1.66
New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept. J Rheumatol (2008) 1.66
Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum (2009) 1.65
Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis. J Rheumatol (2007) 1.63
CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells. Blood (2010) 1.63
Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther (2011) 1.61
Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther (2005) 1.61
The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther (2008) 1.60
Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol (2009) 1.58
Concepts and epidemiology of spondyloarthritis. Best Pract Res Clin Rheumatol (2006) 1.57
The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. Arthritis Res Ther (2008) 1.56
HLA-B27-restricted CD8+ T cell response to cartilage-derived self peptides in ankylosing spondylitis. Arthritis Rheum (2005) 1.55
The place of juvenile onset spondyloarthropathies in the Durban 1997 ILAR classification criteria of juvenile idiopathic arthritis. International League of Associations for Rheumatology. J Rheumatol (2002) 1.55
Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthritis Rheum (2008) 1.53
TNF signaling drives myeloid-derived suppressor cell accumulation. J Clin Invest (2012) 1.52
The small subset of CD56brightCD16- natural killer cells is selectively responsible for both cell proliferation and interferon-gamma production upon interaction with dendritic cells. Eur J Immunol (2004) 1.50
Fractional encoding of harmonic motions in MR elastography. Magn Reson Med (2007) 1.49
MR elastography of the human heart: noninvasive assessment of myocardial elasticity changes by shear wave amplitude variations. Magn Reson Med (2009) 1.47
IL-12-mediated STAT4 signaling and TCR signal strength cooperate in the induction of CD40L in human and mouse CD8+ T cells. Eur J Immunol (2013) 1.45
Autoregulation of Th1-mediated inflammation by twist1. J Exp Med (2008) 1.43
Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Ann Rheum Dis (2010) 1.43
Activation of human NK cells by plasmacytoid dendritic cells and its modulation by CD4+ T helper cells and CD4+ CD25hi T regulatory cells. Eur J Immunol (2005) 1.42
Brain viscoelasticity alteration in chronic-progressive multiple sclerosis. PLoS One (2012) 1.41
Quantitation of simulated short echo time 1H human brain spectra by LCModel and AMARES. Magn Reson Med (2004) 1.41
Vertebral erosions associated with spinal inflammation in patients with ankylosing spondylitis identified by magnetic resonance imaging: changes after 2 years of tumor necrosis factor inhibitor therapy. J Rheumatol (2013) 1.41
The DESIR cohort: a 10-year follow-up of early inflammatory back pain in France: study design and baseline characteristics of the 708 recruited patients. Joint Bone Spine (2011) 1.41
The IkappaB kinase complex and NF-kappaB act as master regulators of lipopolysaccharide-induced gene expression and control subordinate activation of AP-1. Mol Cell Biol (2004) 1.39